MD Anderson experts discuss advances in imaging AI, biomarkers, and proton therapy ahead of the 2025 ASTRO meeting.
Key Details
- 1AI tools are advancing early detection in medical imaging, including lymph node metastases previously missed by standard diagnostics.
- 2Proton therapy is becoming more widespread, with phase III trials (e.g., 440 oropharyngeal cancer patients) showing reduced toxicities versus traditional radiation.
- 3Biomarker research is personalizing prostate cancer care, such as the NRG GU006 trial using genomic tools.
- 4Theranostics and radiopharmaceuticals, like FDA-approved Pluvicto, are expanding from localized to systemic radiation treatments.
- 5MD Anderson researchers are presenting over 65 abstracts at ASTRO covering these innovations.
Why It Matters
AI's integration into medical imaging is quickly improving diagnostic accuracy and treatment personalization in oncology. These advances—especially in clinical trials and real-world applications—are set to directly impact radiology workflows and patient outcomes.
Source
EurekAlert
Related News
•EurekAlert
AI-Based Imaging Biomarker for Chronic Stress Validated on Chest CT
A deep learning model has identified and validated the first imaging biomarker for chronic stress using adrenal gland measurements from routine chest CT scans.
•EurekAlert
Multi-Algorithm Machine Learning Model Enhances Exacerbation Risk Prediction in COPD
A multi-algorithm machine learning model significantly improves risk prediction of acute exacerbations in COPD patients using multidimensional clinical data.
•EurekAlert
AI Simplifies CT Reports, Boosting Cancer Patients' Understanding
AI-driven text simplification significantly improves cancer patients' comprehension of CT scan reports.